FSSAI Nutraceuticals Licensing: 2026 Compliance Guide

What the March 2026 FSSAI Amendments Mean for Nutraceutical Businesses

On 10 March 2026, the Gazette of India published the Food Safety and Standards (Licensing and Registration of Food Businesses) Amendment Regulations, 2026 (Notification No. RCD-01002/1/2021-Regulatory-FSSAI-Part(1)), signed by FSSAI CEO Rajit Punhani. A follow-up implementation order (FSSAI Order No. I/36087/2026, dated 13 March 2026, signed by Director (Regulatory Compliance) Sweety Behera) set revised turnover thresholds effective 1 April 2026. Additionally, the Food Safety and Standards (Labelling and Display) First Amendment Regulations, 2026 were notified on 30 March 2026. For nutraceutical Food Business Operators (FBOs), these changes interact with an already stringent licensing framework — and understanding that interaction is now urgent.

Central Licensing: Non-Negotiable for Nutraceuticals

The single most important rule for any business manufacturing, relabelling, or importing nutraceuticals and health supplements in India has not changed — but the 2026 amendments reinforce it. As confirmed by the updated FoSCoS Kind of Business (KoB) eligibility matrix, nutraceutical and health supplement manufacturers must obtain a Central FSSAI License regardless of annual turnover. The revised thresholds — Registration up to ₹1.5 crore, State License between ₹1.5 crore and ₹50 crore, Central License above ₹50 crore — apply as general criteria for the broader food sector. But the KoB-based override means nutraceutical FBOs cannot use a lower turnover figure to downgrade to a State License. Choosing the wrong licence type on FoSCoS remains a common and costly mistake, capable of delaying your application or triggering outright rejection.

These products are governed by the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2016, which cover eight categories: Health Supplements, Nutraceuticals, Foods for Special Dietary Use, Foods for Special Medical Purpose, Specialty Foods containing plant or botanicals, Foods containing Probiotics, Foods containing Prebiotics, and Novel Foods.

The New Perpetual Validity Rule — and Its Hidden Obligations

One of the most significant changes from the March 2026 reforms is the introduction of perpetual validity. The new Regulation 2.1.7 states that a license or registration certificate granted under these regulations “shall be valid and subsisting, unless otherwise suspended, cancelled or surrendered.” For nutraceutical businesses, this eliminates the previous cycle of periodic renewals — but it does not eliminate compliance obligations.

Failure to pay the annual FSSAI license fee or to submit the Food Safety Compliance Return (FSCR) on the due date will result in deemed suspension of the license. A suspended license can only be revoked after payment of outstanding dues and applicable penalties. The practical message is clear: perpetual validity is not a compliance holiday. For nutraceutical FBOs — whose products face elevated scrutiny given their health claims and active ingredient profiles — a suspension carries reputational and commercial consequences far beyond the administrative inconvenience of a lapsed renewal.

Step-by-Step: How to Apply for a Central FSSAI License for Nutraceuticals

Step 1 — Identify Your Kind of Business (KoB)

Log in to the FoSCoS portal (foscos.fssai.gov.in) and select your KoB carefully. Manufacturers, Relabellers (brand owners using third-party contract manufacturers), and Importers all follow distinct application pathways. Note: the earlier KoB categories of “Supplier” and “Marketer” no longer accept new applications. If your business model involves outsourced manufacturing under your own brand, you must apply as a Relabeller.

Step 2 — Select the Correct Food Category

On FoSCoS, select Category 13.6 (Nutraceuticals) under Category 13 (Foodstuffs Intended for Particular Nutritional Uses). Mis-categorisation is a leading cause of application queries and delays — the Designated Officer (DO) will scrutinise your ingredient list against the approved schedules under the 2016 Regulations.

Step 3 — Compile the Mandatory Document Set

Nutraceutical applications face higher scrutiny than general food license applications. You must submit:

• Form B (completed online via FoSCoS)
• Blueprint/Layout Plan of the manufacturing or processing unit
• Recall and Traceability Plan — a detailed document specifying how defective batches will be identified, withdrawn, and disposed of
• Water Analysis Report from an NABL-accredited laboratory
• Certificate of Analysis (CoA) for raw ingredients and the finished product
• List of Directors/Partners with contact details and government-issued photo ID/address proof
• NOC from Manufacturer (mandatory if you are a Relabeller)
• Food Safety Management System (FSMS) documentation
• For Importers: a valid Importer Exporter Code (IEC)

Step 4 — Pay Government Fees and Await Scrutiny

After submitting Form B with all supporting documents, the DO will verify whether your ingredients are permitted under the 2016 Regulations. If all documents are in order, the 14-digit FSSAI Central License number is generated. The FSSAI verification process can take up to 60 days depending on product complexity and documentation completeness. For health claim approvals (distinct from the license itself), a dossier with a government fee of ₹50,000 must be submitted — the expert committee review timeline is approximately one to eight days for advertisement and claims approval.

Ingredient Compliance: The Red Lines You Cannot Cross

Ingredient selection is where many nutraceutical applications stall or result in post-market enforcement action. The key rules are:

• Nutraceuticals may only contain ingredients specified in the approved Schedules under the 2016 Regulations (Schedules IV and VI for botanical/plant-origin ingredients; Schedules VA, VE, and VF for permitted additives).
• Only probiotic cultures specified in Schedule VII or those subsequently approved by FSSAI may be used in probiotic products.
• For specific health benefit claims, prior approval from FSSAI is mandatory. Therapeutic or curative claims (e.g., “cures arthritis” or “substitute for insulin”) are strictly prohibited.
• FSSAI has directed FBOs to discontinue use of 14 ingredients found to lack adequate scientific safety data, including raspberry ketone, silica, angelica sinensis, saw palmetto, chlorella growth factor, chaga extract, and tea tree oil, among others.
• Caffeine is capped at 200 mg per serving and theobromine at 100 mg per serving.

Labelling Updates Effective 1 July 2026

The FSS (Labelling and Display) First Amendment Regulations, 2026, notified on 30 March 2026, introduce refinements relevant to nutraceutical packaging, including exemptions on RDA (Recommended Daily Allowance) declarations for infant nutrition products and non-retail containers. FSSAI’s standing policy — announced in January 2025 — is that all changes to labelling regulations are enforced from 1 July of the relevant year. Nutraceutical FBOs must audit their existing labels against both the 2016 Regulations and the 2026 amendment before that date.

Additionally, QR code labelling is currently applicable to nutraceuticals priced above ₹1,000, with phased implementation ongoing. Businesses in this price bracket should ensure QR codes on packaging link to complete product information as required.

Food Safety Display Boards (FSDBs) must be displayed at all premises: a Purple/Grey Board for manufacturing/processing units and a Green Board for retail supplement stores. The 14-digit FSSAI license number must appear on all packaging, premises, and invoices.

Enforcement and Penalties

Operating without a valid Central FSSAI License, making unpermitted health claims, using banned ingredients, or selling nutraceuticals whose formulation does not match the licensed product list can result in license cancellation, product recall, seizure of stocks, financial penalties, or imprisonment under the Food Safety and Standards Act, 2006. Under the perpetual validity framework introduced in March 2026, non-payment of annual fees or failure to file FSCR triggers automatic suspension — a new enforcement lever that replaces the passive lapse of a time-bound renewal.

Practical Checklist for Nutraceutical FBOs — Act Now

1. Confirm Central License status — regardless of turnover, verify you hold a valid Central License; State Licenses for nutraceutical manufacturers are not permissible.
2. Schedule your annual fee and FSCR filing — mark the due dates prominently; automatic suspension under the March 2026 rules is swift and requires penalty payment to reverse.
3. Audit your ingredient list against current Schedules and the 14 banned substances list; remove any non-compliant ingredients before your next production run.
4. Review label artwork for QR code compliance (products above ₹1,000) and check alignment with the 30 March 2026 Labelling Amendment ahead of the 1 July 2026 enforcement date.
5. Contract manufacturers must hold valid FSSAI licenses — Relabellers are responsible for ensuring their manufacturing partner’s license is current before accepting any batch.
6. Maintain FSMS records and your Recall Plan as live documents, not one-time application artefacts — inspections under the new risk-based framework will target high-risk categories like nutraceuticals more frequently if compliance history is weak.

ACPL’s regulatory experts can help you navigate FSSAI nutraceuticals licensing and compliance. Contact us at info@acplgroupindia.co.in or call +91-9266665201 for a consultation.